The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Marketing
  • Health
  • Entertainment

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
  • UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • World Cup Crowds Are a Stress Test for America's Restrooms
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
  • Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Pulse Wave is where moments become movements
  • Michigan's Plane Crash Data Points Away from Big Airports
  • 2iG Solutions Launches MGA Insight, Bringing AI-Powered Business Intelligence to Managing General Agents
  • A Better Way to Find a Real Estate Agent Is Coming Soon
  • Talentica Software Earns a Place Among India's Top 100 Great Mid-size Workplaces 2026
  • 4-Week Search for 2 True "Philly Girls" Starts July 8th 2026
  • Socialhose Launches TikTok Investigator, a Platform for Investigating TikTok Live
  • David Pedrol named Managing Director in Indonesia
  • AutomationIQ Launches to Bring Enterprise-Grade AI Automation to Local and Mid-Market Businesses
  • Texas Hospitals & Their Patients Describe Two Very Different Healthcare Systems, New Social Knowing
  • DEPIN Studios Sees Surge in Demand After AI Gaming Launch
  • Discard Junk Removal Named #1 Junk Removal Company in Sacramento Out of 189 Businesses Evaluated
  • J&J Exterminating Mourns the Passing of Founder Bobby John Sr
  • Delirious Comedy Club Transforms Into Las Vegas' Newest Live Comedy Studio With Weekly Delirious TV Tapings
  • BitTitan Advances MigrationWiz with New Capabilities, Platform Enhancements, and Product Leadership Update
  • Sara Abbas Receives "Eniochos" Charioteer Award at 2026 Who is Who International Awards
  • Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm
  • CCHR: DOJ Takedown Exposes Over $220 Million Defrauded in Behavioral Mental Health Fraud Schemes
  • Exeter Smiles Encourages Reading Families to Start Teen Braces This Summer
  • ARC Technologies Announces Corporate Asset Sale of buildings, inventory and IP patents

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 297
  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
  • $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Brilliant Minds to Gather in Fort Worth for National Mensa Event
  • West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
  • Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
  • The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry

Similar on PennZone

  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us